BioMérieux SA

03/27/2024 | Press release | Distributed by Public on 03/27/2024 11:03

bioMérieux receives Dual 510(k) clearance and CLIA-waiver approval for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel

bioMérieux receives Dual 510(k) clearance and CLIA-waiver approval for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel

27 Mar 2024 18:01 CET

Subscribe

Issuer

BIOMERIEUX

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_1240143_PR_bioMrieux_SPOTFIRE_RST_Panel_FDA_Clearance_20240327.pdf

Source

BIOMERIEUX

Provider

Les Echos

Company Name

BIOMERIEUX

ISIN

FR0013280286

Symbol

BIM

Market

Euronext